Couce M, O'Brien T D, Moran A, Roche P C, Butler P C
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA.
J Clin Endocrinol Metab. 1996 Mar;81(3):1267-72. doi: 10.1210/jcem.81.3.8772610.
A high proportion of patients with cystic fibrosis (CF) develop diabetes mellitus. In common with type II diabetes mellitus, diabetes mellitus in CF is characterized by a progressive decline in beta-cell function and an approximately 50% decline in beta-cell mass. It is not known whether islet amyloidosis (characteristic of type II diabetes mellitus) is present in diabetes mellitus complicating CF. To address this, pancreatic samples were obtained at autopsy from 9 control cases (without CF) and 41 cases of CF that were, in turn, subdivided into 13 nondiabetic, 12 borderline diabetic, and 16 diabetic cases based on clinical criteria. Islet amyloid was detected by light microscopy in 69% cases of CF with diabetes mellitus, 17% of cases with borderline diabetes mellitus, and none of the nondiabetic cases. Islet amyloid was not present in any of the control cases. Islet amyloidosis derived from islet amyloid polypeptide is a characteristic feature of diabetes mellitus in CF as well as type II diabetes mellitus.
相当一部分囊性纤维化(CF)患者会患糖尿病。与II型糖尿病一样,CF患者的糖尿病的特征是β细胞功能逐渐下降,β细胞数量减少约50%。目前尚不清楚II型糖尿病特有的胰岛淀粉样变是否存在于合并CF的糖尿病中。为了解决这个问题,对9例对照病例(无CF)和41例CF病例进行了尸检胰腺样本采集,后者又根据临床标准分为13例非糖尿病、12例边缘性糖尿病和16例糖尿病病例。通过光学显微镜在69%的CF糖尿病病例、17%的边缘性糖尿病病例中检测到胰岛淀粉样变,而在非糖尿病病例中未检测到。对照病例中均未出现胰岛淀粉样变。源自胰岛淀粉样多肽的胰岛淀粉样变是CF患者糖尿病以及II型糖尿病的一个特征性表现。